{"id":24081,"date":"2023-07-13T17:21:48","date_gmt":"2023-07-13T11:51:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24081"},"modified":"2023-08-17T11:08:06","modified_gmt":"2023-08-17T05:38:06","slug":"medtech-news-for-resmed-stryker-oncobeta","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta","title":{"rendered":"ResMed Acquired Somnoware; Stryker Launched Q Guidance System; AlloSource\u2019s AceConnex Pre-Sutured Fascia; Urotronic\u2019s Optilume BPH Catheter System; Verve Medical\u2019s Pivotal Trial of RPD Renal Pelvic Denervation System; OncoBeta Provided Update on Rhenium-SCT"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69de6f27414c5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69de6f27414c5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#ResMed_Acquired_Somnoware_a_Leader_in_Digital_Sleep_and_Respiratory_Care_Diagnostics_Software\" >ResMed Acquired Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#Stryker_Launched_Q_Guidance_System_with_Cranial_Guidance_Software\" >Stryker Launched Q Guidance System with Cranial Guidance Software<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#AlloSource_Received_FDA_510K_Clearance_for_AceConnex%E2%84%A2_Pre-Sutured_Fascia_for_Hip_Labral_Reconstruction_and_Augmentation\" >AlloSource Received FDA 510(K) Clearance for AceConnex\u2122 Pre-Sutured Fascia for Hip Labral Reconstruction and Augmentation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#Urotronic_Announced_FDA_Approval_of_Optilume%C2%AE_BPH_Catheter_System\" >Urotronic Announced FDA Approval of Optilume\u00ae BPH Catheter System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#Verve_Medical_Announced_FDA_Approval_of_IDE_for_Pivotal_Trial_of_RPD%E2%84%A2_Renal_Pelvic_Denervation_System_for_Treatment_of_Uncontrolled_Hypertension\" >Verve Medical Announced FDA Approval of IDE for Pivotal Trial of RPD\u2122 Renal Pelvic Denervation System for Treatment of Uncontrolled Hypertension<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\/#OncoBeta%C2%AE_GmbH_Provided_Update_on_Phase_IV_Clinical_Trial\" >OncoBeta\u00ae GmbH Provided Update on Phase IV Clinical Trial<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-resmed-acquired-somnoware-a-leader-in-digital-sleep-and-respiratory-care-diagnostics-software\"><span class=\"ez-toc-section\" id=\"ResMed_Acquired_Somnoware_a_Leader_in_Digital_Sleep_and_Respiratory_Care_Diagnostics_Software\"><\/span><strong>ResMed Acquired Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 05, 2023, <\/strong>ResMed acquired privately held Somnoware, a US leader in sleep and respiratory care diagnostics software.&nbsp;<\/p>\n\n\n\n<p>The Somnoware software streamlines the processes of physicians as well as sleep and pulmonary function testing labs for diagnosing and evaluating a patient\u2019s sleep and respiratory care test results. The software is also used for ordering PAP treatment equipment, setting up appointments, tracking PAP compliance, and electronically providing this information directly into a patient\u2019s electronic health record.<\/p>\n\n\n\n<p>ResMed intends to retain all Somnoware staff, integrate its offerings into the ResMed brand and solution ecosystem, and maintain the open and device-agnostic nature of Somnoware\u2019s offerings so end users can keep interoperating with various testing solutions and place orders for treatment devices and accessories from any supplier.<\/p>\n\n\n\n<p>The transaction\u2019s financial terms are not material to ResMed\u2019s consolidated financial results and were not disclosed.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled to welcome the Somnoware team to ResMed,<\/em>\u201d said ResMed Sleep &amp; Respiratory Care President Lucile Blaise. Lucile Blaise added, <em>\u201cWe\u2019re committed to driving wider adoption of Somnoware\u2019s open and interoperable platform to help more people with OSA or COPD get the diagnoses and treatment solutions they need. Improving patients\u2019 experience and health outcomes is our common goal.\u201d&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are very excited about this acquisition,\u201d<\/em> said ResMed North America General Manager Bill Shoop. Bill Shoop further said, <em>\u201cSomnoware\u2019s offering has been well received in the marketplace, and it naturally complements our ecosystem of digital solutions across the patient care pathway. Our team is excited to add Somnoware to our portfolio of solutions to help physicians, sleep labs, and HMEs drive greater efficiency and deliver better patient care.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cI\u2019m thrilled to join forces with ResMed and embark on a shared mission of guiding people toward better sleep and improved breathing. Our partnership will open new avenues to help physicians with the critical task of chronic care management,\u201d<\/em> said Subath Kamalasan, Somnoware co-founder and CEO. Subath Kamalasan also commented, <em>\u201cTogether, we are committed to driving innovation and delivering solutions that improve the health of patients with sleep disorders and other chronic respiratory diseases.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/sleep-tech-devices-market\"><strong>Sleep Tech Devices Market<\/strong><\/a>\u201d report, the global sleep tech devices market was valued at <strong>USD 16,941.46 million<\/strong> in 2022, growing at a <strong>CAGR <\/strong>of <strong>17.31%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 44,038.42 million<\/strong> by 2028. The demand for sleep tech devices is primarily being boosted by the increasing patient population suffering from various sleep disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/insomnia-market\"><strong>insomnia<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\"><strong>obstructive sleep apnea<\/strong><\/a>, and others, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\"><strong>surge in cases of depression<\/strong><\/a>, increasing number of risk factors such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><strong>obesity<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/smoking-cessation-and-nicotine-addiction-market\"><strong>smoking<\/strong><\/a> among others associated with causing poor sleep, rise in the number of sleep awareness campaigns and programs highlighting the importance of sleep, and innovation in product development among others, thereby contributing to the overall growth of the sleep tech devices market during the forecast period from 2023-2028.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-stryker-launched-q-guidance-system-with-cranial-guidance-software\"><span class=\"ez-toc-section\" id=\"Stryker_Launched_Q_Guidance_System_with_Cranial_Guidance_Software\"><\/span><strong>Stryker Launched Q Guidance System with Cranial Guidance Software<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 11, 2023<\/strong>, Stryker, one of the world\u2019s leading medical technology companies, launched its Q Guidance System with Cranial Guidance Software to provide surgeons with an image-based planning and intraoperative guidance system that assists in positioning instruments and identifying patient anatomy during cranial surgery. The software can be used for craniotomies, skull base and transsphenoidal procedures, shunt placements, and biopsies.&nbsp;<\/p>\n\n\n\n<p>The Q Guidance System with Cranial Guidance Software uses both active and passive tracking technology to provide ground-breaking planning and guidance capabilities that include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Proprietary camera: The new 4th generation FP8000 camera offers increased speeds compared to products currently offered in the market<\/li>\n\n\n\n<li>Dual PC system: One PC powers the operating system&#8217;s applications while the other provides real-time patient data<\/li>\n\n\n\n<li>Diffusion Tensor Imaging (DTI) and tractography: DTI uses anisotropic diffusion to estimate the brain&#8217;s axonal organization, reconstructed in 3D<\/li>\n\n\n\n<li>Precision Targeting System: Enables navigated biopsy of cranial tissue by using comprehensive guidance data and imaging to pre-plan an approach for an entry point<\/li>\n\n\n\n<li>Electromagnetic catheter placement: Enables pinless shunt procedures<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith Cranial Guidance Software powered by Q, neurosurgeons have more surgical planning and guidance capabilities than ever before, with a special focus on biopsies and shunt placements,\u201d<\/em> said Robbie Robinson, president of Stryker\u2019s Spine division. Robbie Robinson added, <em>\u201cThis technology has the potential to become the standard of care and a possible means to increase accuracy and efficiency in the operating room.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith Stryker\u2019s new camera technology, we were able to quickly register patients using the CranialMask Tracker,\u201d<\/em> said Dr. J.D. Day, M.D. of UAMS Health in Little Rock, Arkansas. Dr. J.D. further commented, <em>\u201cThe new user interface and workflows are slick, and our staff loves the intuitive new views like 3D targeting and the new skull stripping feature.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/image-guided-surgery-devices-market\"><strong>Image-Guided Surgery Devices<\/strong> <strong>Market<\/strong><\/a>\u201d report, the global image-guided surgery devices market was valued at <strong>USD 5,540.87 million<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>5.81%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 7,765.22 million<\/strong> by 2028. The image-guided surgery devices market is observing remarkable market growth due to the factors such as the escalating burden of the geriatric population prone to chronic diseases and the rising prevalence of chronic diseases such as <a href=\"https:\/\/www.delveinsight.com\/blog\/cardiovascular-disease-landscape\"><strong>cardiovascular<\/strong><\/a>, cancers, neurological, and others across the globe. Further, a gradual increase in approval of image-guided surgery devices, rapid technological advancement in the products, increasing <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>demand for minimally invasive surgeries<\/strong><\/a>, and others will create a necessity for Image Guided Surgery Devices in the market. Therefore, the market for image-guided surgery devices is estimated to grow at a substantial CAGR during the forecast period from 2023 to 2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-allosource-received-fda-510-k-clearance-for-aceconnex-pre-sutured-fascia-for-hip-labral-reconstruction-and-augmentation\"><span class=\"ez-toc-section\" id=\"AlloSource_Received_FDA_510K_Clearance_for_AceConnex%E2%84%A2_Pre-Sutured_Fascia_for_Hip_Labral_Reconstruction_and_Augmentation\"><\/span><strong>AlloSource Received FDA 510(K) Clearance for AceConnex\u2122 Pre-Sutured Fascia for Hip Labral Reconstruction and Augmentation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 11, 2023<\/strong>, AlloSource\u00ae, one of the largest allograft providers creating innovative cellular and tissue products to help surgeons heal their patients, received the U.S. Food and Drug Administration\u2019s 510(K) clearance of AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation. This product reinforces AlloSource\u2019s commitment to providing innovative products to support the overall sports medicine market, including hip arthroscopy.<\/p>\n\n\n\n<p>The AceConnex Pre-Sutured Fascia is a tool used in soft tissue surgeries where constructs, particularly those with allograft tissue, are employed for labrum reconstruction, replacement, or augmentation. The sterile, ready-to-use device will come in a variety of pre-sutured sizes and have trimmable sections that enable allograft changes to fit patients&#8217; anatomy.&nbsp; In contrast to allografts that are manually sutured pre-operatively, AceConnex Pre-Sutured Fascia is manufactured to assure consistency and minimize variability. Fascia allografts have a long history of being used successfully for labral reconstruction.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAceConnex Pre-Sutured Fascia was designed to help hip arthroscopists efficiently treat their patients by eliminating time and tedious effort associated with suturing in the OR,\u201d<\/em> said Carolyn Rorick, AlloSource Senior Director of Product Development, Innovation, and Clinical Affairs. Carolyn also said, <em>\u201cWe spent an extensive amount of time perfecting our design and suturing technique to ensure consistency, and that design is now patented.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAceConnex Pre-Sutured Fascia is integral to our mission of providing innovative allografts to advance patient healing,\u201d <\/em>said Dean Elliott, AlloSource President, and CEO. Dean Elliott further added, <em>\u201cWe are proud to be first to market with an FDA-cleared pre-sutured fascia device to meet the varying needs of hip arthroscopists and patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-sutures-market\"><strong>Surgical Sutures Market<\/strong><\/a>\u201d report, the global surgical sutures market was valued at <strong>USD 3.56 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>6.64%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 5.24 billion<\/strong> by 2028. The increase in demand for surgical sutures is predominantly attributed to the rise in the volume of surgeries worldwide. Moreover, an increase in various diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\"><strong>arthritis<\/strong><\/a>, spinal deformities, and cancers, among others which require surgery for their management, a rise in non-fatal injuries, growing approval of products, and launches of various advanced surgical sutures are anticipated to bolster the demand for these sutures thereby leading to an increase in the global market for surgical sutures during the forecasted period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-urotronic-announced-fda-approval-of-optilume-bph-catheter-system\"><span class=\"ez-toc-section\" id=\"Urotronic_Announced_FDA_Approval_of_Optilume%C2%AE_BPH_Catheter_System\"><\/span><strong>Urotronic Announced FDA Approval of Optilume\u00ae BPH Catheter System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>July 11, 2023,<\/strong> Cardio Flow Design Inc., a medical device company developing and commercializing Optilume\u00ae, a proprietary drug-coated balloon technology that provides a minimally invasive treatment option for men suffering from urinary tract conditions like urethral strictures and benign prostatic hyperplasia (BPH), announced that it had received U.S. Food and Drug Administration (FDA) approval of its Optilume\u00ae BPH Catheter System, a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for the treatment of lower urinary tract symptoms (LUTS) secondary to BPH.&nbsp;<\/p>\n\n\n\n<p>Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while the delivery of paclitaxel is intended to maintain luminal patency during healing.<\/p>\n\n\n\n<p>Optilume BPH is a minimally invasive outpatient procedure engineered to alleviate urinary symptoms caused by BPH, a condition affecting 70% of men 60-69 years of age and 80% of those 70 or older. By combining mechanical dilation with the safe and proven drug paclitaxel, the Optilume BPH Catheter System achieves an anterior commissurotomy, while the delivery of paclitaxel is intended to maintain luminal patency during healing.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWith the highest reported Qmax in BPH MIST trials to date, Optilume BPH is the next generation of minimally invasive technology, creating a new drug-device space among BPH therapies,\u201d<\/em> said Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York. <em>\u201cThe positive data from the PINNACLE and EVEREST trials demonstrate clear and compelling sustained clinical outcomes through four years post-treatment,\u201d<\/em> also said Dr. Kaplan.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThere\u2019s nothing else like Optilume BPH that\u2019s currently available. It\u2019s the only treatment option that requires no cutting, burning, steaming, or implants,\u201d <\/em>said Urotronic President and CEO David Perry. David Perry also said, <em>\u201cThis advancement, backed by strong clinical outcomes, has the potential to improve the quality of life for millions of patients looking for a solution for BPH and its associated lower urinary tract symptoms. Drug-coated balloons are the future of interventional urology.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/urinary-catheters-market\"><strong>Urinary Catheters Market<\/strong><\/a>\u201d report, the global urinary catheters market was valued at <strong>USD 3.29 billion<\/strong> in 2022, growing at a <strong>CAGR <\/strong>of <strong>6.64%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 4.82 billion<\/strong> by 2028. The increase in <a href=\"https:\/\/www.delveinsight.com\/report-store\/external-urinary-catheters-market\"><strong>demand for urinary catheters<\/strong><\/a> is predominantly attributed to the growing cases of urological disorders such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/urinary-incontinence-market\"><strong>urinary incontinence<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/urinary-incontinence-market\"><strong>benign prostatic hyperplasia<\/strong><\/a>, among others, rising old age population across the globe, increase in the number of surgical procedures, and advancement in the materials used to manufacture urinary catheters, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-verve-medical-announced-fda-approval-of-ide-for-pivotal-trial-of-rpd-renal-pelvic-denervation-system-for-treatment-of-uncontrolled-hypertension\"><span class=\"ez-toc-section\" id=\"Verve_Medical_Announced_FDA_Approval_of_IDE_for_Pivotal_Trial_of_RPD%E2%84%A2_Renal_Pelvic_Denervation_System_for_Treatment_of_Uncontrolled_Hypertension\"><\/span><strong>Verve Medical Announced FDA Approval of IDE for Pivotal Trial of RPD\u2122 Renal Pelvic Denervation System for Treatment of Uncontrolled Hypertension<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> July 11, 2023, <\/strong>Verve Medical, Inc., an early-stage medical device company, received approval from the US Food &amp; Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL-Denervation) Pivotal IDE trial for the treatment of uncontrolled hypertension to lower blood pressure.<\/p>\n\n\n\n<p>The Verve RPD, NOVEL Pivotal trial will be an up to 300 patients, Phase II\/I randomized, sham-controlled, double-blinded study to determine the safety and efficacy of the Verve RPD minimally invasive, non-vascular renal pelvic denervation system to treat hypertension.<\/p>\n\n\n\n<p>Verve&#8217;s method, like a typical urology treatment, accesses the renal nerves through the normal aperture of the urethra, in contrast to other renal denervation approaches that use the renal artery. The increased density of innervation in the renal pelvis, where access is simpler than with the conventional arterial renal denervation strategy, likely makes the Verve RPD system, which ablates afferent and efferent nerves, more successful.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe Verve RPD, NOVEL \u2013 Denervation, Pivotal trial will be another critical milestone toward making this differentiated therapy available to helping the over one billion uncontrolled hypertension patients worldwide, including 80 million in the U.S, who struggle with managing this serious condition,\u201d <\/em>said Verve President and CEO, David Springer. David further added,<em> \u201cThis Pivotal trial is designed to provide the basis for approval of the procedure in the US.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-drugs-market\"><strong>Hypertension Drugs Market<\/strong><\/a>\u201d report, the global hypertension drugs market is estimated to grow at a <strong>CAGR<\/strong> of <strong>3.3%<\/strong> during the forecast period from 2023 to 2028. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-pipeline-insight\"><strong>demand for hypertension drugs<\/strong><\/a> is primarily being boosted by the growing <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-epidemiology-forecast\"><strong>prevalence of hypertension<\/strong><\/a>, the rising number of obese and overweight individuals, growing awareness of high blood pressure and related consequences, and rising cases of psychiatric comorbidities associated with uncontrolled hypertension, among others further contributing in the overall <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-market\"><strong>growth of the hypertension drugs market<\/strong><\/a> during the forecast period from 2023-2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-oncobeta-gmbh-provided-update-on-phase-iv-clinical-trial\"><span class=\"ez-toc-section\" id=\"OncoBeta%C2%AE_GmbH_Provided_Update_on_Phase_IV_Clinical_Trial\"><\/span><strong>OncoBeta\u00ae GmbH Provided Update on Phase IV Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>July 11, 2023<\/strong>, OncoBeta\u00ae GmbH, a medical device company specializing in innovative epidermal radioisotope therapies, confirmed the Phase IV international multi-center study designed to further evaluate the Complete Response Rate of <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonmelanoma-skin-cancer-epidemiology-forecast\"><strong>patients with non-melanoma skin cancer<\/strong><\/a> after treatment with Rhenium-SCT\u00ae is now fully recruited.<\/p>\n\n\n\n<p>The EPIC-Skin study (Efficacy of Personalised Irradiation with Rhenium-SCT for the treatment of non-melanoma skin cancer) is based on the proven effect of the \u00df-emitter rhenium-188 in the treatment of basal cell (BCC) and squamous cell carcinomas (SCC).&nbsp;<\/p>\n\n\n\n<p>The study aims to further evaluate the efficacy of Rhenium-SCT\u00ae as well as important Patient Reported Outcome Measures such as quality of life, treatment comfort, and cosmetic outcomes.<\/p>\n\n\n\n<p>The Rhenium-SCT is a painless, single-session, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonmelanoma-skin-cancer-market\"><strong>treatment of NMSCs (non-melanoma skin cancers)<\/strong><\/a>. The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed for treatment without affecting the healthy tissue.<\/p>\n\n\n\n<p>Patients treated with therapy had confirmed histopathology of stage I or II non-melanoma skin cancer. With the latest treatment round complete, all patients are now in the follow-up phase, which monitors the quality of life, treatment comfort, and cosmetic outcomes over the next 24 months. An interim analysis is expected to be published in mid-2023.<\/p>\n\n\n\n<p>The EPIC-Skin study is being conducted across five countries and seven major cities, including Rostock, Vienna, London, Pretoria, Gold Coast, Perth, and Sydney, with more than 180 patients taking part.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Dr. Gerhard Dahlhoff, Medical Director at OncoBeta\u00ae GmbH, stated, <em>&#8220;We are excited to complete the final patient recruitment within EPIC-Skin as we will now start to receive data on the quality-of-life outcomes. With patients in study centers across Australia, Austria, Germany, the United Kingdom, and South Africa, we have a mix of patients, ethnicities, NMSC localisations, and lesion characteristics, which will enable us to even further evaluate the outcomes of treatment with Rhenium-SCT\u00ae.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Shannon D. Brown III, CEO, and Managing Director at OncoBeta\u00ae GmbH, said, <em>&#8220;The patient journey is often a difficult one, so the medical community must continue to improve and develop new treatment options for patients with NMSCs. The EPIC-Skin clinical study has the potential to influence and change the way we evaluate and fit NMSC treatments to the individual needs and requirements of patients.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/radiotherapy-or-radiation-oncology-devices-market\"><strong>Radiotherapy\/Radiation Oncology Devices Market<\/strong><\/a>\u201d report, the global radiotherapy\/radiation oncology devices market is projected to grow at a <strong>7.78%CAGR<\/strong> during the forecast period (2023-2028). The radiotherapy\/radiation oncology devices market is witnessing positive growth owing to factors such as the rising cases of various cancers, further rapid technological developmental activities, strong R&amp;D initiatives from key players, rising adoption of radiotherapy procedures in cancer treatment, growing demand for minimally invasive procedures, thereby contributing to the growth of the radiotherapy\/radiation oncology devices market during the forecast period from 2023-2028.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ResMed Acquired Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software On July 05, 2023, ResMed acquired privately held Somnoware, a US leader in sleep and respiratory care diagnostics software.&nbsp; The Somnoware software streamlines the processes of physicians as well as sleep and pulmonary function testing labs for diagnosing and evaluating a patient\u2019s [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":24084,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[21083,21082,4044,21086,19354,2753,16779,18996,16975,18799,420,21088,19871,21079,21081,19949,19950,21080,17053,19034,21084,21085],"industry":[17226],"therapeutic_areas":[17228,17243,17506],"class_list":["post-24081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-allosource","tag-diagnostics-software","tag-hypertension","tag-hypertension-drugs-market","tag-image-guided-surgery-devices-market","tag-medical-device","tag-medtech","tag-medtech-devices","tag-medtech-market","tag-medtech-news","tag-news","tag-oncobeta","tag-radiation-oncology-devices-market","tag-resmed","tag-respiratory-care-diagnostics","tag-sleep-tech-devices","tag-sleep-tech-devices-market","tag-somnoware","tag-stryker","tag-surgical-sutures","tag-surgical-sutures-market","tag-verve-medical","industry-medical-devices","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | ResMed, Stryker, OncoBeta, Urotronic, AlloSource<\/title>\n<meta name=\"description\" content=\"ResMed Acquired Somnoware; Stryker&#039;s Q Guidance System; AlloSource\u2019s AceConnex; Urotronic\u2019s Optilume BPH Catheter System; OncoBeta\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | ResMed, Stryker, OncoBeta, Urotronic, AlloSource\" \/>\n<meta property=\"og:description\" content=\"ResMed Acquired Somnoware; Stryker&#039;s Q Guidance System; AlloSource\u2019s AceConnex; Urotronic\u2019s Optilume BPH Catheter System; OncoBeta\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-13T11:51:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T05:38:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | ResMed, Stryker, OncoBeta, Urotronic, AlloSource","description":"ResMed Acquired Somnoware; Stryker's Q Guidance System; AlloSource\u2019s AceConnex; Urotronic\u2019s Optilume BPH Catheter System; OncoBeta","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta","og_locale":"en_US","og_type":"article","og_title":"MedTech News | ResMed, Stryker, OncoBeta, Urotronic, AlloSource","og_description":"ResMed Acquired Somnoware; Stryker's Q Guidance System; AlloSource\u2019s AceConnex; Urotronic\u2019s Optilume BPH Catheter System; OncoBeta","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-07-13T11:51:48+00:00","article_modified_time":"2023-08-17T05:38:06+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta","name":"MedTech News | ResMed, Stryker, OncoBeta, Urotronic, AlloSource","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta.png","datePublished":"2023-07-13T11:51:48+00:00","dateModified":"2023-08-17T05:38:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"ResMed Acquired Somnoware; Stryker's Q Guidance System; AlloSource\u2019s AceConnex; Urotronic\u2019s Optilume BPH Catheter System; OncoBeta","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-resmed-stryker-oncobeta#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta.png","width":772,"height":482,"caption":"MedTech News for ResMed, Stryker, OncoBeta"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/07\/13171153\/MedTech-News-for-ResMed-Stryker-OncoBeta-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AlloSource<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diagnostics Software<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hypertension Drugs Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Image Guided Surgery Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OncoBeta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Radiation Oncology Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ResMed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Respiratory Care Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sleep Tech Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sleep Tech Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Somnoware<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stryker<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Sutures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Sutures Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Verve Medical<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AlloSource<\/span>","<span class=\"advgb-post-tax-term\">Diagnostics Software<\/span>","<span class=\"advgb-post-tax-term\">hypertension<\/span>","<span class=\"advgb-post-tax-term\">Hypertension Drugs Market<\/span>","<span class=\"advgb-post-tax-term\">Image Guided Surgery Devices Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">MedTech<\/span>","<span class=\"advgb-post-tax-term\">MedTech Devices<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">OncoBeta<\/span>","<span class=\"advgb-post-tax-term\">Radiation Oncology Devices Market<\/span>","<span class=\"advgb-post-tax-term\">ResMed<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Care Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Sleep Tech Devices<\/span>","<span class=\"advgb-post-tax-term\">Sleep Tech Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Somnoware<\/span>","<span class=\"advgb-post-tax-term\">Stryker<\/span>","<span class=\"advgb-post-tax-term\">Surgical Sutures<\/span>","<span class=\"advgb-post-tax-term\">Surgical Sutures Market<\/span>","<span class=\"advgb-post-tax-term\">Verve Medical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jul 13, 2023","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on Jul 13, 2023 5:21 pm","modified":"Updated on Aug 17, 2023 11:08 am"},"featured_img_caption":"MedTech News for ResMed, Stryker, OncoBeta","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24081"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24084"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24081"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24081"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}